October 29, 2020 02:00 AM EDT

Sanofi teams up with Merck to pair Keytruda with a next-gen IL-2 candidate from the Synthorx buyout

Nicole DeFeudis

Editor

Nearly a year after snapping up a next-gen immuno-oncology candidate in its $2.5 billion Synthorx buyout, Sanofi is joining forces with Merck to pair …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi teams up with Merck to pair Keytruda with a next-gen IL-2 candidate from the Synthorx buyout

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Nvidia-backed Achira debuts, blending AI and physics to model molecules

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sanofi teams up with Mer­ck to pair Keytru­da with a next-gen IL-2 can­di­date from the Syn­thorx buy­out

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi teams up with Merck to pair Keytruda with a next-gen IL-2 candidate from the Synthorx buyout